Results 21 to 30 of about 342 (145)

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus [PDF]

, 2020
© 2019 The Authors Background: Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis. Objective: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD.
Clucas, Alan, Alexis, Andrew, Lindsey, Lisa, Wollenberg, Andreas, Bouaziz, Jean-David, Ahmad, Faiz, Silverberg, Jonathan I., Bouaziz, Jean David, Pinter, Andreas, Piketty, Christophe, Murrell, Dédée F., Poulin, Yves, Pulka, Grazyna   +12 more
core   +1 more source

Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues

Frontiers in Medicine, 2021
Pruritus represents one of the most common symptoms in dermatology and general medicine. Chronic pruritus severely impairs the quality of life of affected patients.
Jana Maria Nemmer, Marcus Kuchner, Angeliki Datsi, Angeliki Datsi, Péter Oláh, Péter Oláh, Valérie Julia, Ulrike Raap, Bernhard Homey   +8 more
doaj   +1 more source

Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study

, 2021
© 2021 Galderma SA. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Pinter, A., Chaouche, K., J.M. Armstrong, C. Piketty, J.‐D. Bouaziz, Murrell, D. F., J.I. Silverberg, A. Wollenberg, Lynde, C., Wollenberg, A., Armstrong, J. M., V. Laquer, C. Lynde, S. Alpizar, F. Ahmad, A. Pinter, Alpizar, S., Silverberg, J. I., K. Chaouche, Bouaziz, J. D., Piketty, C., Ahmad, F., Alavi, A., A. Alavi, D.F. Murrell, Laquer, V.   +25 more
core   +1 more source

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis

Acta Dermato-Venereologica
Nemolizumab with background topical therapy (corticosteroids±calcineurin inhibitors) significantly improved skin lesions, itch and sleep in two global phase 3 trials (ARCADIA 1&2) in adolescents and adults with moderate-to-severe atopic dermatitis ...
Andreas Wollenberg, Jonathan I. Silverberg, Franz J. Legat, Marie Tauber, Vivian T. Laquer, April W. Armstrong, Andrew E. Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty   +19 more
doaj   +1 more source

Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis

Frontiers in Medicine, 2022
IntroductionPruritus is a major and burdensome symptom in atopic dermatitis (AD). The number of systemic treatments available for AD has increased recently, enabling improved patient relief.ObjectiveTo evaluate the effect of AD treatments on pruritus ...
Youna Rodriguez-Le Roy, Anne-Sophie Ficheux, Laurent Misery, Laurent Misery, Emilie Brenaut, Emilie Brenaut   +5 more
doaj   +1 more source

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances

, 2022
BACKGROUNDPatients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a high burden of disease, primarily due to the intensity of the itch.
F. Ahmad, G. Yosipovitch, Ständer, S, K. Chaouche, Chaouche, K, C. Piketty, Piketty, C, Ahmad, F, A. Reich, Legat, F J, Lacour, J-P, C. Paul, J.‐P. Lacour, Reich, A, S. Ständer, Yosipovitch, G, Paul, C, F.J. Legat   +17 more
core   +1 more source

Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence

Journal of Dermatological Treatment
Background Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain.Objective To synthesize efficacy, safety and strength of evidence for ...
Mohammed Shanshal, Aarthy Uthayakumar
doaj   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Role of Nemolizumab and Omalizumab in management of atopic dermatitis: A review [PDF]

, 2021
BackgroundNemolizumab (CIM331) is a monoclonal antibody that binds the IL-31 receptor α component. This inhibits IL-31 from acting on neurons that constrains the initialization of the sense of pruritus in cases of atopic dermatitis.AimsTo summarize the ...
Yousef Ali H Alaenzi; Aseer central Hospital, Abha , Saudi Arabia, Mohammed Abdulhafith R Alotaibi; Aseer central Hospital, Abha , Saudi Arabia, Sultan Makki M Alsharef; Aseer central Hospital, Abha , Saudi Arabia, Yousef Hussain J Alharthi; Aseer central Hospital, Abha , Saudi Arabia, Ibrahim Mahmoud H Ajwah; King Salman Armed Forced Hospital, Tabuk, Saudi Arabia, Ahmed Bakheet N Alharbi; King Salman Armed Forced Hospital, Tabuk, Saudi Arabia, Shifa Sameer A Nagadi; Dammam medical city, Dammam, Saudi Arabia, Maram Salim S Algrani; University of Tabuk, Saudi Arabia, Ali Abdulrahman A Alshehri; Aseer central Hospital, Abha , Saudi Arabia, Rayyan Fahad H Altemani; Aseer central Hospital, Abha , Saudi Arabia, Muneera Saeed F Alhayan; Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Omnia Abdulmonum A Alali; Aseer central Hospital, Abha , Saudi Arabia, Shumoukh Saleh F AlAfnan; University of Hail, Saudi Arabia, Ahmed Saad A Albalawi; Aseer central Hospital, Abha , Saudi Arabia, Zahra Shaker H Al-kalaif; Hera General Hospital, Makkah, Saudi Arabia   +14 more
core  

Table_4_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.docx

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source